

Supplementary information




Figure S1. A and B, Genomic enrichment analysis (GSEA) of high/low expression groups of centrosome-related genes




Figure S2. Kaplan-Meier analysis of progression free survival curves for TCGA patients in the DRGs high/low groups.




Figure S3. A to T, Kaplan-Meier analysis of OS curves in patients with high and low immunocompetence differences.




Figure S4. mRNA expression of SAR1A, NPM1, NMP3, CTTN, CSNK2A2, PIK3R3, PCID2, MARK4 and CCNA1 between normal and tumor in TCGA.

Table S1 Primer sequences used for Q-PCR and Real-time PCR

Gene Name	Primer	Sequence
<i>CCNA1</i>	Forward	GCACACTCAAGTCAGACCTGCA
	Reverse	ATCACATCTGTGCCAAGACTGGA
<i>PIK3R3</i>	Forward	CCACCTAACCCAATGACTTCAGC
	Reverse	GTTGAGGCATCTCGGACCAAGA
<i>CSNK2A2</i>	Forward	CGACCATCAACAGAGACTGACTG
	Reverse	GTGAGACCCTGGAAAGCACAG
<i>CTTN</i>	Forward	AGGTGTCCTCTGCCTACCAGAA
	Reverse	CCTGCTCTTCTCCTTAGCGAG
<i>NMP3</i>	Forward	TGACCATCAGGAGATCGCAGTC
	Reverse	TTCAGGCGGAAGGTTACAGGTG
<i>NPM1</i>	Forward	GCCAGTGCATATTAGTGGACAGC
	Reverse	GGAACCTTGCTACCACCTCCAG
<i>PCID2</i>	Forward	CTGCGGAATCTCCTCATCCTG
	Reverse	GGCAACCAGAAAAGCATCCAGAG
<i>SAR1A</i>	Forward	GGGCTTATGGACAGACCACAG
	Reverse	CCGTAACCTTGCCTTTGAGCA
<i>MARK4</i>	Forward	GTCAACAGACTGTGAGAGCATCC
	Reverse	GCTCTGTGTATGGCTTCAACTCC
<i>ACTB</i>	Forward	CACCATTGGCAATGAGCGGTTTC
	Reverse	AGGTCTTGCAGATGTCCACGT